NASDAQ:OVIDOvid Therapeutics Stock Price, Forecast & News

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, OVID shares have increased by 166.4% and is now trading at $7.14.
View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ovid Therapeutics.

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for Ovid Therapeutics.

Ovid Therapeutics Inc (NASDAQ:OVID) released its quarterly earnings results on Monday, August, 10th. The company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.05.
View Ovid Therapeutics' earnings history.

8 analysts have issued 1 year price targets for Ovid Therapeutics' stock. Their forecasts range from $9.00 to $21.00. On average, they expect Ovid Therapeutics' stock price to reach $13.33 in the next twelve months. This suggests a possible upside of 86.7% from the stock's current price.
View analysts' price targets for Ovid Therapeutics.

Headlines about OVID stock have been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ovid Therapeutics earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Ovid Therapeutics.

Ovid Therapeutics saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 2,530,000 shares, a drop of 30.1% from the June 30th total of 3,620,000 shares. Based on an average daily volume of 1,500,000 shares, the short-interest ratio is currently 1.7 days. Currently, 8.6% of the shares of the company are sold short.
View Ovid Therapeutics' Short Interest.

Some companies that are related to Ovid Therapeutics include INDIVIOR PLC/S (INVVY), MacroGenics (MGNX), Rocket Pharmaceuticals (RCKT), Akebia Therapeutics (AKBA), ZEALAND PHARMA/S (ZEAL), Myovant Sciences (MYOV), Portola Pharmaceuticals (PTLA), Zymeworks (ZYME), Heron Therapeutics (HRTX), Intra-Cellular Therapies (ITCI), Innoviva (INVA), Mersana Therapeutics (MRSN), Zogenix (ZGNX), Amneal Pharmaceuticals (AMRX) and Epizyme (EPZM).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Gilead Sciences (GILD), VBI Vaccines (VBIV) and Selecta Biosciences (SELB).

(OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.93%), Platinum Investment Management Ltd. (0.55%), UBS Group AG (0.24%), Virtus ETF Advisers LLC (0.12%), New York State Common Retirement Fund (0.07%) and SG Americas Securities LLC (0.04%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda.
View institutional ownership trends for Ovid Therapeutics.

OVID stock was sold by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., and UBS Group AG.
View insider buying and selling activity for Ovid Therapeutics.

OVID stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Virtus ETF Advisers LLC, New York State Common Retirement Fund, SG Americas Securities LLC, State Board of Administration of Florida Retirement System, Aigen Investment Management LP, Strs Ohio, and Ameritas Investment Partners Inc.. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin, Karen Bernstein, and Pharmaceutical Co Ltd Takeda.
View insider buying and selling activity for Ovid Therapeutics.

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OVID stock can currently be purchased for approximately $7.14.

Ovid Therapeutics has a market capitalization of $390.94 million. The company earns $-60,460,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Ovid Therapeutics employs 59 workers across the globe.

The official website for Ovid Therapeutics is www.ovidrx.com.

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]